Axis-Shield gains Sangui CDT (carbohydrate deficient transferrin) line as firms settle:
This article was originally published in Clinica
Executive Summary
Sangui Biotech has agreed to stop selling its kits worldwide within 90 days after the company reached agreement with Anglo-Norwegian company Axis-Shield regarding alleged patent infringement on Axis' carbohydrate deficient transferrin (%CDT) assay. In addition, Sangui, of Santa Ana, California, is to sell to Upton, Cambridgeshire-based Axis its CDT business, used for the detection of excessive alcohol consumption, for $100,000.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.